On June 25, the "Summer Davos Forum" 2025 was held in Tianjin. Premier Li Qiang of the State Council attended the opening ceremony and a symposium with representatives from the business community. The Chief Executive Officer of Sino Biopharm (1177.HK) was invited to participate in this symposium and deliver a speech at the Bioeconomy Forum. This conference brought together over 1,700 representatives from politics, business, and academia from more than 90 countries and regions to deeply explore the "Entrepreneurship in the New Era" that will drive the future, focusing on five major themes: "Decoding the Global Economy", "China Outlook", "Industries in Transformation", "Investing in People and the Planet", and "New Energy and Materials".

At the symposium, Premier Li Qiang pointed out that the current international situation is undergoing profound and complex changes, posing significant challenges to the economic development of all countries. China's economy has maintained a stable growth trend, not only due to its sound fundamentals and proactive macroeconomic policies but also because of the great importance placed on leveraging the power of the market and enterprises, in which foreign-invested enterprises have made significant contributions. At the same time, China has also provided a broad space for the development of foreign-invested enterprises. Premier Li Qiang expressed his hope that enterprises from all countries will provide more high-quality products and services to the Chinese market, strengthen cooperation with Chinese companies in technology and industry, better match supply and demand for mutual benefit, and jointly promote technological progress and enhance industrial competitiveness. China will, as always, welcome enterprises from all countries to invest and do business in China, and looks forward to everyone realizing their dreams and achieving success here, accompanying the steady and long-term development of the Chinese economy.

Mr. Eric Tse, who was invited to the symposium, stated during the exchange that Sino Biopharm will continue to deepen its presence in the Chinese market, continuously increase investment in technological innovation, and achieve greater corporate development by integrating into China's high-quality development process.

In the "Who Will Lead the Bioeconomy" session, Mr. Eric Tse first reviewed the rapid development of China's biopharmaceutical industry, pointing out that the number of innovator drugs from China has entered the top tier globally. In 2024, innovative drugs first approved in China accounted for 38% of the global total, with First-in-Class (FIC) drugs making up 31%. At the annual meeting of the American Society of Clinical Oncology (ASCO), considered a bellwether for the global pharmaceutical industry, more than 70 research findings by Chinese scholars were selected for oral presentations this year, and Sino Biopharm set a new record for a Chinese pharmaceutical company with 12 oral presentations. He stated that the innovative achievements of China's biopharmaceutical industry are inseparable from the joint efforts of the government, research institutions, and enterprises, especially a series of policy supports promoting development in fields such as innovative drugs and synthetic biology.

Mr. Eric Tse also emphasized that compared to Western countries, China still lacks world-class biopharmaceutical companies and needs to continue its efforts in original innovation, accumulation of fundamental theories and core underlying technologies, as well as deep integration of industry, academia, and research. He looks forward to further planning and building high-level industrial clusters with distinct characteristics and a division of labor by strengthening top-level design and regional coordination, deepening collaborative innovation across the entire industry, forming a complementary synergy, and avoiding homogeneous competition. In particular, he called for increased efforts to cultivate "world-class" leading biopharmaceutical enterprises to drive the industry chain to accelerate breakthroughs and move towards the high end. He called for multi-party collaboration to expand the global layout of the industrial chain, strengthen global innovation cooperation, and contribute to the further development of the global health industry.

Subsequently, Mr. Eric Tse engaged in in-depth discussions with the attendees on topics such as the global competitiveness and national resilience of China's bioeconomy, and AI-empowered breakthroughs in biopharmaceutical innovation.

Declaration:

The copyright of this article is owned by the original author or our company. Unauthorized use by means of reprinting, copying, filming, adapting, or compiling is prohibited. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited.

Source: Xinhua News Agency, 2025 Summer Davos Forum